IL272262A - Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one - Google Patents

Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one

Info

Publication number
IL272262A
IL272262A IL272262A IL27226220A IL272262A IL 272262 A IL272262 A IL 272262A IL 272262 A IL272262 A IL 272262A IL 27226220 A IL27226220 A IL 27226220A IL 272262 A IL272262 A IL 272262A
Authority
IL
Israel
Prior art keywords
pyrazolo
pyrimidin
dihydro
analogs
Prior art date
Application number
IL272262A
Other languages
English (en)
Hebrew (he)
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of IL272262A publication Critical patent/IL272262A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL272262A 2017-08-01 2020-01-26 Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one IL272262A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762539734P 2017-08-01 2017-08-01
PCT/US2018/044580 WO2019028008A1 (en) 2017-08-01 2018-07-31 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Publications (1)

Publication Number Publication Date
IL272262A true IL272262A (en) 2020-03-31

Family

ID=65233095

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272262A IL272262A (en) 2017-08-01 2020-01-26 Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one

Country Status (16)

Country Link
US (2) US11124518B2 (enExample)
EP (1) EP3661918B1 (enExample)
JP (1) JP7203816B2 (enExample)
KR (1) KR20200034781A (enExample)
CN (1) CN111094253B (enExample)
AR (1) AR112774A1 (enExample)
AU (1) AU2018312448B2 (enExample)
BR (1) BR112020002104A2 (enExample)
CA (1) CA3071405A1 (enExample)
ES (1) ES2980537T3 (enExample)
IL (1) IL272262A (enExample)
MX (1) MX2020001235A (enExample)
RU (1) RU2020105058A (enExample)
SG (1) SG11202000789WA (enExample)
TW (1) TW201910335A (enExample)
WO (1) WO2019028008A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
CA3088997A1 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
BR112020018286A2 (pt) * 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
CN110872296B (zh) * 2018-08-31 2023-05-23 上海弘翊生物科技有限公司 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用
JP2022526831A (ja) * 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
US20220169646A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210380A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
BR112021026618A2 (pt) 2019-06-28 2022-06-07 Shanghai Pharmaceuticals Holding Co Ltd Composto de pirazolpirimidina, método de preparação do mesmo e aplicações do mesmo
CN112142748B (zh) * 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
CA3165472A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
CA3182270A1 (en) * 2020-05-15 2021-11-18 Recurium Ip Holdings, Llc Mono- and combination therapies
AU2021290701A1 (en) 2020-06-17 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
CN114805357B (zh) * 2021-01-21 2023-12-19 四川大学 一种靶向setdb1-ttd的小分子抑制剂及其制药用途
EP4332104A4 (en) * 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
US20240254123A1 (en) * 2021-06-04 2024-08-01 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
CN117751122B (zh) * 2021-08-11 2026-07-24 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023045942A1 (zh) * 2021-09-22 2023-03-30 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
WO2026112362A1 (en) * 2024-11-21 2026-05-28 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5190271B2 (ja) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としての5員の環付加複素環式ピリミジン
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
EP2213673B1 (en) * 2007-10-23 2013-06-05 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
SMT201900344T1 (it) * 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP3661918C0 (en) 2024-05-08
EP3661918A1 (en) 2020-06-10
US20200157112A1 (en) 2020-05-21
EP3661918B1 (en) 2024-05-08
JP2020529993A (ja) 2020-10-15
CA3071405A1 (en) 2019-02-07
MX2020001235A (es) 2020-07-20
RU2020105058A3 (enExample) 2021-11-17
AU2018312448B2 (en) 2022-09-15
US11124518B2 (en) 2021-09-21
TW201910335A (zh) 2019-03-16
RU2020105058A (ru) 2021-09-02
EP3661918A4 (en) 2021-05-12
US20210317124A1 (en) 2021-10-14
BR112020002104A2 (pt) 2020-08-04
AU2018312448A1 (en) 2020-02-13
SG11202000789WA (en) 2020-02-27
JP7203816B2 (ja) 2023-01-13
AR112774A1 (es) 2019-12-11
KR20200034781A (ko) 2020-03-31
WO2019028008A1 (en) 2019-02-07
CN111094253B (zh) 2023-08-29
ES2980537T3 (es) 2024-10-01
CN111094253A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
SG11202000789WA (en) 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
IL276802A (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidin-3-ones
SG11202002653UA (en) Formulations
ZA201705802B (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
IL250823A0 (en) A new derivative of 6,5-dihydro-h4-benzo[b]thiano-[3,2-d]azepine
GB2589796B (en) Long-offset acquisition
SG11201801365YA (en) NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF
IL248277A0 (en) Compounds of the type: 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yl amides
IL254167A0 (en) Combinations containing modified 3,2-dihydroimidazo[2,1-c]quinazoline
IL257757A (en) Substituted 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds
IL273387A (en) Thylanstatin analogs
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
CA185995S (en) One-piece garment
CA185993S (en) One-piece garment
CA185994S (en) One-piece garment
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
CA185991S (en) One-piece garment
IL258217A (en) 2,3,4,5 tetrahydropyridin-6-amine derivatives
CA185992S (en) One-piece garment
HK40027677A (en) 1, 2-dihydro-3h-pyrazolo [3, 4-d]pyrimidin-3-one analogs
HK40033093A (en) Thailanstatin analogs
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
PH32018000939S1 (en) Coaster
HUP1700542A2 (en) Nucleosides modified by 5'-linker